← ANALYST RATINGS · TIPRANKS
Collegium Pharmaceutical (COLL): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy1 Hold0 Sell
Ratings of 7 analysts in the last 3 months12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $48.71, the highest $60.00, the lowest $43.00. The average is +110.1% from the last price of $23.19.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $23.50 → $25.00+6.4% | Hold | +7.8% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $23.50 → $25.00+6.4% | Hold | +7.8% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $23.00 → $24.50+6.5% | Hold | +5.6% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $21.50 → $23.50+9.3% | Hold | +1.3% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $23.00 → $25.00+8.7% | Hold | +7.8% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $24.50 → $26.00+6.1% | Buy | +12.1% | Upgrade | 17.10.26on TipRanks 00:06 | — | |
| Jenna Davidner★★★★★★★★★★#10265 · hits 25% · avg −5.3% | Barclays | $48.00 | Buy | +107.0% | Reiterated | 15.10.26on TipRanks 05:07 | +2.7%next day +1.1% | ↗ |
| Les Sulewski★★★★★★★★★★#1947 · hits 51% · avg +11.5% | Truist Financial | $50.00 | Buy | +115.6% | Reiterated | 09.10.26on TipRanks Oct 12 05:50 | −0.7%next day −0.1% · 5 days +6.9% | ↗ |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | $60.00 | Buy | +158.7% | Reiterated | 21.09.26on TipRanks 13:55 | −0.4%next day −1.1% · 5 days −0.8% | ↗ |
| Daniel Clark★★★★★★★★★★#3492 · hits 65% · avg +17.4% | Leerink Partners | $45.00 | Buy | +94.0% | Initiated | 09.09.26on TipRanks 08:25 | +0.4%next day −1.3% · 5 days −3.9% | ↗ |
| Name not given | — | $58.00 → $49.00−15.5% | Buy | +111.3% | Initiated | 09.09.26on TipRanks 07:08 | +0.4%next day −1.3% · 5 days −3.9% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $45.00 → $43.00−4.4% | Hold | +85.4% | Reiterated | 07.08.26on TipRanks 08:01 | +0.6%next day −7.7% · 5 days −4.6% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | $56.00 → $46.00−17.9% | Buy | +98.4% | Reiterated | 06.08.26on TipRanks 14:10 | −18.4%next day +0.6% · 5 days −4.5% | ↗ |
| Unknown Analyst | Jefferies | $51.00 | Buy | +119.9% | Reiterated | 20.03.26on TipRanks 14:42 | −0.9%next day −3.0% · 5 days −6.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Collegium Pharmaceutical
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $48.71 at a price of $21.82 (+123.3%); now: $48.71 at $23.19 (+110.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 5 | 4 | 4 | 8 | 9 |
| Buy | 4 | 3 | 3 | 0 | 0 | 0 |
| Hold | 3 | 2 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.86 (from $1.72 to $1.97). Last quarter: $1.92.
Sales
Next quarter’s sales estimate — $216M (from $214M to $221M). Last quarter: $200M.
Best top-analyst consensus in the sector · Healthcare
About Collegium Pharmaceutical
- CEO: Vikram Karnani
- Employees: 423
- 100 Technology Center Drive, Stoughton, MA, 02072, US
- www.collegiumpharma.com
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Data from the stock’s TipRanks forecast page, read 34 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗